SAR 126119

Drug Profile

SAR 126119

Alternative Names: SAR126119

Latest Information Update: 20 May 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi
  • Class Anti-ischaemics
  • Mechanism of Action Carboxypeptidase U inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I Stroke

Most Recent Events

  • 08 Jan 2013 Phase II development is ongoing in France
  • 31 Dec 2011 Sanofi completes a phase I trial in Stroke in France during 2011
  • 28 Jul 2011 Phase-I clinical trials in Stroke in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top